FiercePharma

BREO™ ELLIPTA™ gains US approval for the treatment of COPD

LONDON and SOUTH SAN FRANCISCO, Calif., May 10, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration ...
FiercePharma

FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US

LONDON and SAN FRANCISCO, April 30, 2015 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ...
Business Wire

Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ®, ANORO ® ELLIPTA ®. In addition, Innoviva retains a 15 percent economic ...
Medical Xpress

FDA OKs Glaxo's inhaler, first one to combine three medicines

The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday approved sales of ...
Business Wire

Breo Ellipta (GlaxoSmithKline/Innoviva) Drug Outlook to 2026: A Combination of Fluticasone Furoate & Vilanterol Indicated for the Treatment of Asthma & COPD ...

DUBLIN--(BUSINESS WIRE)--The "Breo Ellipta" report has been added to ResearchAndMarkets.com's offering. Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol ...
Monthly Prescribing Reference

Breo Ellipta

Fluticasone furoate, vilanterol 100/25mcg, 200/25mcg; per inh; dry pwd for oral inh. Increased risk of asthma-related events (death, hospitalizations, intubations) with LABA monotherapy (without ICS).
Washington Examiner

FDA panel backs inhaler drug for lung disease

WASHINGTON (AP) — A panel of respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease. A majority of ...
FierceBiotech

FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in ...
FierceBiotech

BREO™ ELLIPTA™ gains US approval for the treatment of COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily ...
Seattle Times

FDA OKs Glaxo’s inhaler, first one to combine 3 medicines

TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday ...
Fox Business

FDA OKs Glaxo's inhaler, first one to combine 3 medicines

The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis. The FDA late Monday approved sales of ...